Sutro Biopharma (STRO) Return on Sales (2017 - 2025)

Sutro Biopharma has disclosed Return on Sales across 9 years of filings, most recently posting 0.07% for Q4 2025.

• Return on Sales for Q4 2025 came in at 0.07%, down 17.0% year-over-year; the trailing twelve-month figure through Dec 2025 was 0.02% (down 2.0% YoY), and the FY2025 annual result was 0.02%, down 2.0% from the prior year.
• Return on Sales came in at 0.07% for Q4 2025 at Sutro Biopharma, down from 0.06% in the prior quarter.
• In the past five years, Return on Sales ranged from a high of 0.1% in Q4 2024 to a low of 0.11% in Q1 2025.
• The 5-year median for Return on Sales is 0.04% (2021), against an average of 0.03%.
• Across the five-year window, Return on Sales climbed 10 bps in 2024 and slipped 17 bps in 2025, its largest moves.
• Sutro Biopharma's Return on Sales stood at 0.04% in 2021, then slipped by 12 bps to 0.04% in 2022, then soared by 107 bps to 0.0% in 2023, then soared by 3673 bps to 0.1% in 2024, then tumbled by 169 bps to 0.07% in 2025.
• The last three Return on Sales figures came in at 0.07% (Q4 2025), 0.06% (Q3 2025), and 0.0% (Q2 2025), per Business Quant data.